Pacira BioSciences, Inc. — Form 10-Q
Filed August 4, 2026 · analyzed by the Periodic Agent
10-Q
▲ Likely positive
significance 72/100
What the filing says
Zimmer, Inc. agreed to acquire all shares of Pacira CryoTech, Inc. (a handheld cryoanalgesia device company) from Pacira BioSciences, Inc. for $70M base consideration (dated June 28, 2026). Additional contingent payments: up to $70M in milestone payments tied to Net Revenue thresholds ($50M–$70M) over 2027–2031, plus $1M Spasticity Collaborative Adjustment. Asset Purchase Price is $34.85M; Share Purchase Price is the remainder. Significant representations cover FDA/regulatory compliance, IP ownership, no material litigation, and employee matters. Seller subject to 5-year non-compete and 10-year confidentiality covenants.
Why this rating
Sale of subsidiary business unit at material valuation (~$70M base = 9% of market cap, potentially $140M total with milestones = 18.5%) represents significant value realization event. Removes development-stage medical device business from Pacira portfolio; material but not transformational for 757M company.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.